Figure 1 Suggested biopsy-avoiding diagnostic pathway for coeliac disease Figure 1 | Suggested biopsy-avoiding diagnostic pathway for coeliac disease.

Slides:

Advertisements

Similar presentations

Recognition and assessment of coeliac disease Implementing NICE guidance 2009 NICE clinical guideline 86.

Advertisements

SCREENING FOR CELIAC DISEASE IN EGYPTIAN CHILDREN SCREENING FOR CELIAC DISEASE IN EGYPTIAN CHILDREN Prof. Dr: Mona Abu Zekry -Professor of Pediatrics Head.

Dept. of 1 Public Health and Clinical Medicine, Epidemiology and Public Health Sciences, Umeå University; 2 Pediatrics, Lund University; 3 Pediatrics,

The near future, applications and activities G. Magazzù and L. Greco.

‘National Pictures of Celiac Disease ‘ GREECE Roma Eleftheria Professor of Paediatric Gastroenterology University of Athens Naples, September 2010.

Zrinjka Mišak Referral Centre for Paediatric Gastroenteorology and Nutrition Children’s Hospital Zagreb Zagreb, Croatia Checking the quality of diagnostic.

How to really implement a control quality ? Virtut Velmishi « Mother Teresa Hospital » Tirana-Albania 1 SERVICE OF PEDIATRIC GASTROHEPATOLOGY.

Figure 4 PET imaging in experimental pancreatic cancer

Figure 1 Proposed risk stratification for patients with NAFLD

Figure 2 Endoscopic imaging of intestinal villi

Correlation of Duodenal Histology With Tissue Transglutaminase and Endomysial Antibody Levels in Pediatric Celiac Disease Matthew R. Donaldson, Sean.

Figure 4 Activation of clopidogrel via cytochrome P450

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 6 Injection of mesenchymal stem cells in perianal fistulas

Figure 2 A stage-based approach to the treatment of NAFLD

Figure 5 Lipid droplet consumption

Figure 3 Semantic model of the active surveillance (AS) timeline

Nat. Rev. Nephrol. doi: /nrneph

Figure 1 Worldwide incidence of CCA

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 2 The microbiome–gut–brain axis

The prospective study and the new ESPGHAN protocol

Figure 1 Organs involved in coeliac-disease-associated autoimmunity

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 1 Biosimilar development process

Figure 3 Algorithm from working group describing

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 2 Effect of PPIs on gastric physiology

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 4 Giant lipid droplet formation

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 6 Combination therapy for HCC

Figure 2 Modelling the effect of HCV treatment on reinfection in people who inject drugs Figure 2 | Modelling the effect of HCV treatment on reinfection.

Figure 2 Switching of biologic agents and biosimilars

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 3 High-resolution manometry of achalasia subtypes

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 3 Example wireless motility recording

to the liver and promote patient-derived xenograft tumour growth

Figure 7 Example colonic high-resolution manometry

Figure 1 Environmental factors contributing to IBD pathogenesis

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 3 Clinical algorithms in the management of NASH and diabetes mellitus Figure 3 | Clinical algorithms in the management of NASH and diabetes mellitus.

Figure 2 13C-octanoic acid gastric emptying breath test

Figure 1 Median coverage and distribution by

in the UK (1961–2012), France (1961–2014) and Italy (1961–2010)

Figure 5 Chrononutrition in the liver

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 6 Possible therapeutic targets to decrease hepatic steatosis

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 6 Assessment of colonic transit time with radiopaque markers

Figure 5 Systems biological model of IBS

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Features and Progression of Potential Celiac Disease in Adults

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

IgA (green) and transglutaminase 2 (TG2, red) in the normal jejunum (A, D, G), in the early developing stage of coeliac disease (B, E, H) and in the coeliac.

Figure 2 Lifelong influences on the gut microbiome from

Figure 2 Classifications and appearance of CCAs

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

SERVICE OF PEDIATRIC GASTROHEPATOLOGY

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Presentation transcript:

Figure 1 Suggested biopsy-avoiding diagnostic pathway for coeliac disease Figure 1 | Suggested biopsy-avoiding diagnostic pathway for coeliac disease. Non-biopsy diagnosis of coeliac disease based on the European Society for the Study of Paediatric Gastroenterology, Hepatology and Nutrition criteria in a symptomatic child with strongly positive tissue transglutaminase 2 antibody (anti-TG2) values, >10 times the upper limit of normal (ULN), a positive endomysial IgA antibody (EMA) on another blood sample and the presence of the appropriate HLA type. On the right is the process for an asymptomatic or at-risk child. A positive anti-TG2 result should lead to biopsies and histological analysis for diagnosis. Reilly, N. R. et al. (2017) Coeliac disease: to biopsy or not? Nat. Rev. Gastroenterol. Hepatol. doi:10.1038/nrgastro.2017.121